ClinicalTrials.gg
TerminatedNCT03627091CARMEN CD 307Updated Mar 31, 2022Results posted

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

A Phase 3 interventional study of Ontamalimab and Placebo in Crohn's Disease, sponsored by Shire. Terminated at 281 sites in 34 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
39th of 51
40 · median 100
Started
2019
with 5 others
Phase 3
25 of 86
6 open now
Registered
39th of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 39th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2019, is one of 25 in phase 3, and was the 39th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's disease
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and/or their parent or legally authorized representative (LAR) must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • Participants must be able to voluntarily provide written, signed, and dated (personally or via a LAR) and/or assent, as applicable, to participate in the study.
  • Participants must have completed the 16-week induction treatment period from study SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) and met the following criteria at baseline in maintenance study SHP647-307:

    1. Meet endoscopic response criteria of a reduction in SES-CD from induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) baseline by greater than or equal to >=25% at Week 16 of induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) or
    2. Meet at least 1 of the following 4 criteria at baseline in maintenance study SHP647-307, in addition to no worsening of endoscopic score as measured by SES-CD relative to induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) baseline:
  • Achieving clinical remission as determined by meeting the criteria for clinical remission using the 2-item PRO, that is, 2-item PRO sub scores of average worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days* and average daily stool type frequency \<=2 of type 6/7 (very soft stools/liquid stools) as shown in the Bristol Stool Form Scale (BSFS) over the 7 most recent days*.
  • A decrease of at least 100 points in CDAI score (CDAI-100) from induction studies baseline.
  • A decrease of >=30% and at least 2 points from induction studies baseline in the average daily worst abdominal pain over the 7 most recent days*, with the average daily stool frequency of type 6/7 (very soft stools/liquid stools) either: (i) not worsening from induction studies baseline and/or (ii) meeting the criteria for clinical remission, that is, 2-item PRO subscore of average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as shown in the BSFS over the 7 most recent days*.
  • A decrease of >=30% from induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) baseline in the average daily stool frequency of type 6/7 (very soft stools/liquid stools) as shown in the BSFS over the 7 most recent days*, with the average daily worst abdominal pain either: (i) not worsening from induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) baseline and/or (ii) meeting the criteria for clinical remission, that is, 2-item PRO sub score of average worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days*.

    *Note: The 7 days may or may not be contiguous during the 10 days of data collection before colonoscopy preparation, depending on days to be excluded because of missing data. If fewer than 7 days are available, the criterion will be calculated on all available most recent 6 or 5 days. If fewer than 5 days are available, the criterion will be treated as missing.

  • Participants receiving any treatments for CD are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period of time.

Exclusion criteria

Exclusion Criteria:

  • Participants who had major protocol deviations (as determined by the sponsor) in induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823).
  • Participants who permanently discontinued product because of an AE, regardless of relatedness to investigational product, in induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823).
  • Participants who are likely to require surgery for CD during the study period, except minor interventions (eg, seton placement for anal fistulas).
  • Participants are females who became pregnant during induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823), females who are lactating, females who are planning to become pregnant during the study period, or males or females of not agreeing to continue acceptable methods (ie, highly effective methods for female participants and medically appropriate methods for male participants) through the conclusion of study participation.
  • Participants who do not agree to postpone donation of any organ or tissue, including male participants who are planning to bank or donate sperm and female participants who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
  • Participants who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
  • Participants who have developed obstructive colonic stricture, or enterovesical or enterovaginal fistulae during the induction study SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823).
  • Participants who have a newly diagnosed or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
  • Participants who have developed any major illness/condition or evidence of an unstable clinical condition (example [eg,] renal, hepatic, hematologic, gastrointestinal (except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study.
  • Participants with any other severe acute or chronic medical or psychiatric condition or laboratory or abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Participants with known exposure to Mycobacterium tuberculosis (TB) since testing at screening in induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) and who have been advised to require treatment for latent or active disease but who are without a generally accepted course of treatment.
  • Participants with any of the following abnormalities in hematology and/or serum chemistry profiles during the evaluation of the last visit in the induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823). If the results are considered by the investigator to be transient and inconsistent with the participant's clinical condition, may be repeated once prior to enrollment in Study SHP647-307.

    1. (ALT) and aspartate aminotransferase levels >= 3.0 × the (ULN).
    2. Total level >=1.5 × ULN or >2.0 × ULN if the participant has a known documented history of Gilbert's syndrome.
    3. level \<=80 gram per liter (g/L) (8.0 gram per deciliter [g/dL]).
    4. count \<=100 × 10\^9/L (100,000 cells per cubic millimeter [mm\^3]) or >=1000 × 10\^9/L (1,000,000 cells/mm\^3).
    5. White blood cell count \<=3.5 × 10\^9/L (3500 cells/mm\^3).
    6. \<2 × 10\^9/L (\<2000 cells/mm\^3)
    7. Serum creatinine level >1.5 × ULN or estimated \<30 milliliter per minute (mL/min)/1.73 m\^2 based on the abbreviated Modification of Diet in Renal Disease Study Equation.

      • Note: If platelet count is \<150,000 cells/mm\^3, a further evaluation should be performed to rule out cirrhosis, unless another etiology has already been identified.
  • Participants who are investigational site staff members or relatives of those site staff members or participants who are sponsor employees directly involved in the conduct of the study.
  • Participants who are participating in other investigational studies (other than induction studies SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]) or plan to participate in other investigational studies during this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ontamalimab 25 mg

    Participants will receive 25 mg of ontamalimab subcutaneous (SC) injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).

    Drug: Ontamalimab

  • Experimental
    Ontamalimab 75 mg

    Participants will receive 75 mg of ontamalimab SC injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).

    Drug: Ontamalimab

  • Placebo comparator
    Placebo

    Participants will receive placebo matched with ontamalimab SC injection using prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).

    Other: Placebo

Interventions

  • SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.

    Also known as: SHP647, PF-00547659

  • OtherPlacebo

    SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinical Remission at Week 52

    Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point numerical rating scale \[NRS\] ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the Bristol Stool Form Scale (BSFS) over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or discontinuation before Week 52 were considered failures. Number of participants with clinical remission at Week 52 were reported.

    Time frame: At Week 52

  2. Number of Participants With Enhanced Endoscopic Response at Week 52

    Enhanced endoscopic response was defined as a decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) of at least 50 percent (%) from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\] baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 52 or who discontinued before Week 52 were considered non responders. Number of participants with enhanced endoscopic response at Week 52 were reported.

    Time frame: At Week 52

Secondary outcomes

  1. Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 52

    Clinical remission was defined as a CDAI score of \<150. CDAI assessed CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with clinical remission as measured by CDAI at Week 52 were reported.

    Time frame: At Week 52

  2. Number of Participants With Glucocorticoid-free Clinical Remission at Week 52

    Glucocorticoid-free clinical remission defined as clinical remission by 2-item PRO not requiring any treatment with glucocorticoids for at least 12 weeks prior to Week 52 visit. Clinical remission defined by 2-item PRO sub-scores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency\<=2 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or who discontinued before Week 52 were non-responders. Number of participants with glucocorticoid-free clinical remission response at Week 52 were reported.

    Time frame: At Week 52

  3. Number of Participants With Clinical Remission Defined by Crohn's Disease (CD) E-diary Sub-scores- at Week 52

    Clinical remission was defined by CD daily e-diary 2-item PRO subscores of average daily abdominal pain \<=1 (based on the 4 point scale, with scores ranging from 0 \[none\] to 3 \[severe\]) over the 7 most recent days and average daily stool frequency \<=3 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with clinical remission based on Crohn's Disease (CD) e-diary Sub-scores for abdominal pain was was reported.

    Time frame: At Week 52

  4. Number of Participants With Sustained Clinical Remission at Week 52

    Sustained clinical remission was defined as clinical remission by 2-item PRO at both Week 52 visit and the maintenance baseline in this Study. Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Number of participants with sustained clinical remission at Week 52 were reported.

    Time frame: At Week 52

  5. Number of Participants With Sustained Enhanced Endoscopic Response at Week 52

    Sustained enhanced endoscopic response was defined as enhanced endoscopic response at both Week 52 visit and the maintenance baseline in this study. Enhanced endoscopic response was defined as a decrease in SES-CD of at least 50 % from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]) baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Number of participants with sustained enhanced endoscopic response at Week 52 were reported.

    Time frame: At Week 52

  6. Number of Participants With Clinical Remission Based on 2-item PRO With Enhanced Endoscopic Response at Week 52

    Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days and average daily stool frequency \<= 2 of Type 6/7 (very soft stools/liquid stools) as shown in the BSFS over the 7 most recent days. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Enhanced endoscopic response was defined as a decrease in SES-CD of at least 50% from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]) baseline. Participants with missing data at Week 52 or who discontinued before Week 52 were considered non-responders.

    Time frame: At Week 52

  7. Number of Participants With Complete Endoscopic Healing at Week 52

    Complete endoscopic healing was defined as SES-CD scale score from 0-2. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with complete endoscopic healing at Week 52 were reported.

    Time frame: At Week 52

07

Results

Posted Mar 31, 2022
Limitations and caveats
The study was closed early as the sponsor discontinued the ontamalimab clinical trial program in CD for reasons unrelated to safety or efficacy.

Participant flow

The study was conducted at 33 sites between 06 February 2019 (first participant first visit) and 13 September 2021 (last participant last visit). 278 sites were initiated in this study, but only 33 sites had enrolled participants.

Participant flow — Overall Study
MilestonePlaceboOntamalimab 25 mgOntamalimab 75 mg
Started191011
Completed746
Not completed1265
Withdrew: Adverse event002
Withdrew: Withdrawal by subject202
Withdrew: Physician decision200
Withdrew: Site terminated by sponsor010
Withdrew: Disease relapse751
Withdrew: Other100

Outcome measures

PrimaryNumber of Participants With Clinical Remission at Week 52

Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point numerical rating scale \[NRS\] ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the Bristol Stool Form Scale (BSFS) over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or discontinuation before Week 52 were considered failures. Number of participants with clinical remission at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission at Week 52235
PrimaryNumber of Participants With Enhanced Endoscopic Response at Week 52

Enhanced endoscopic response was defined as a decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) of at least 50 percent (%) from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\] baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 52 or who discontinued before Week 52 were considered non responders. Number of participants with enhanced endoscopic response at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Enhanced Endoscopic Response at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Enhanced Endoscopic Response at Week 52246
SecondaryNumber of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 52

Clinical remission was defined as a CDAI score of \<150. CDAI assessed CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with clinical remission as measured by CDAI at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 52847
SecondaryNumber of Participants With Glucocorticoid-free Clinical Remission at Week 52

Glucocorticoid-free clinical remission defined as clinical remission by 2-item PRO not requiring any treatment with glucocorticoids for at least 12 weeks prior to Week 52 visit. Clinical remission defined by 2-item PRO sub-scores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency\<=2 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or who discontinued before Week 52 were non-responders. Number of participants with glucocorticoid-free clinical remission response at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Glucocorticoid-free Clinical Remission at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Glucocorticoid-free Clinical Remission at Week 52213
SecondaryNumber of Participants With Clinical Remission Defined by Crohn's Disease (CD) E-diary Sub-scores- at Week 52

Clinical remission was defined by CD daily e-diary 2-item PRO subscores of average daily abdominal pain \<=1 (based on the 4 point scale, with scores ranging from 0 \[none\] to 3 \[severe\]) over the 7 most recent days and average daily stool frequency \<=3 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with clinical remission based on Crohn's Disease (CD) e-diary Sub-scores for abdominal pain was was reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Defined by Crohn's Disease (CD) E-diary Sub-scores- at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Defined by Crohn's Disease (CD) E-diary Sub-scores- at Week 52237
SecondaryNumber of Participants With Sustained Clinical Remission at Week 52

Sustained clinical remission was defined as clinical remission by 2-item PRO at both Week 52 visit and the maintenance baseline in this Study. Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Number of participants with sustained clinical remission at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Sustained Clinical Remission at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Sustained Clinical Remission at Week 52212
SecondaryNumber of Participants With Sustained Enhanced Endoscopic Response at Week 52

Sustained enhanced endoscopic response was defined as enhanced endoscopic response at both Week 52 visit and the maintenance baseline in this study. Enhanced endoscopic response was defined as a decrease in SES-CD of at least 50 % from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]) baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Number of participants with sustained enhanced endoscopic response at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Sustained Enhanced Endoscopic Response at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Sustained Enhanced Endoscopic Response at Week 52123
SecondaryNumber of Participants With Clinical Remission Based on 2-item PRO With Enhanced Endoscopic Response at Week 52

Clinical remission was defined by 2-item PRO sub-scores of average worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days and average daily stool frequency \<= 2 of Type 6/7 (very soft stools/liquid stools) as shown in the BSFS over the 7 most recent days. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Enhanced endoscopic response was defined as a decrease in SES-CD of at least 50% from induction study (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]) baseline. Participants with missing data at Week 52 or who discontinued before Week 52 were considered non-responders.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on 2-item PRO With Enhanced Endoscopic Response at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on 2-item PRO With Enhanced Endoscopic Response at Week 52034
SecondaryNumber of Participants With Complete Endoscopic Healing at Week 52

Complete endoscopic healing was defined as SES-CD scale score from 0-2. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 52 or who discontinued before Week 52 were considered failures. Number of participants with complete endoscopic healing at Week 52 were reported.

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Number of Participants With Complete Endoscopic Healing at Week 52
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Complete Endoscopic Healing at Week 52033

Adverse events

Collected over From start of study drug administration up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/19 (0%)1/19 (5.3%)9/19 (47.4%)
Ontamalimab 25 mg0/10 (0%)0/10 (0%)5/10 (50%)
Ontamalimab 75 mg0/11 (0%)2/11 (18.2%)8/11 (72.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboOntamalimab 25 mgOntamalimab 75 mg
Ileal perforationGastrointestinal disorders0/190/101/11
AppendicitisInfections and infestations0/190/101/11
PeritonitisInfections and infestations0/190/101/11
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/101/11
Crohn's diseaseGastrointestinal disorders1/190/100/11
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPlaceboOntamalimab 25 mgOntamalimab 75 mg
HypertensionVascular disorders0/190/102/11
Crohn's diseaseGastrointestinal disorders3/191/101/11
ArthralgiaMusculoskeletal and connective tissue disorders2/191/101/11
LeukocytosisBlood and lymphatic system disorders0/191/100/11
ThrombocytosisBlood and lymphatic system disorders0/191/100/11
Anal fissureGastrointestinal disorders0/191/100/11
ConjunctivitisInfections and infestations0/191/100/11
Corona virus infectionInfections and infestations0/191/100/11
Limb injuryInjury, poisoning and procedural complications0/191/100/11
SciaticaNervous system disorders0/191/100/11

Baseline characteristics

The safety set consisted of all participants who have received at least one dose of investigational product (IP) in the SHP647-307 study regardless of treatment received during the induction studies (either SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).

Age, Continuous
Age, Continuous(Years)PlaceboOntamalimab 25 mgExperimental: Ontamalimab 75 mgTotal
Mean37.7 ± 14.2638.4 ± 7.1845.8 ± 14.8540.1 ± 13.23
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOntamalimab 25 mgExperimental: Ontamalimab 75 mgTotal
Female76518
Male124622
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOntamalimab 25 mgExperimental: Ontamalimab 75 mgTotal
Hispanic or Latino0213
Not Hispanic or Latino1981037
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOntamalimab 25 mgExperimental: Ontamalimab 75 mgTotal
American Indian or Alaska Native0101
Asian1001
Native Hawaiian or Other Pacific Islander0011
Black or African American1001
White1781035
More than one race0000
Unknown or Not Reported0101
08

Study locations

281 sites
  • Arizona Digestive Health Mesa - East
    Mesa, Arizona 85206, United States
  • Elite Clinical Studies - Phoenix - Clinedge - PPDS
    Phoenix, Arizona 85018, United States
  • CATS Research Center - University of Arizona
    Tucson, Arizona 85724, United States
  • Atria Clinical Research - Clinedge - PPDS
    Little Rock, Arkansas 72209, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • OM Research LLC - Lancaster - ClinEdge - PPDS
    Lancaster, California 93534, United States
  • Alliance Clinical Research-(Vestavia Hills)
    Poway, California 92064, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Care Access Research, San Pablo
    San Pablo, California 94806, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80903, United States
  • Asthma and Allergy Associates PC - CRN - PPDS
    Colorado Springs, Colorado 80907, United States
  • Renaissance Research Medical Group, INC
    Cape Coral, Florida 33991, United States
  • Gastro Florida
    Clearwater, Florida 33756, United States
  • Advanced Clinical Research Network
    Coral Gables, Florida 33134, United States
  • Alliance Medical Research LLC
    Coral Springs, Florida 33071, United States
  • SIH Research
    Kissimmee, Florida 34741, United States
  • Crystal Biomedical Research
    Miami Lakes, Florida 33065, United States
  • Hi Tech and Global Research, LLc
    Miami, Florida 33135, United States
  • Sanchez Clinical Research, Inc
    Miami, Florida 33157, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Pharma Research International Inc
    Naples, Florida 34110, United States
  • Omega Research Consultants LLC - Clinedge - PPDS
    Orlando, Florida 32810, United States
  • Accel Research Sites - St. Petersburg - ERN - PPDS
    Pinellas Park, Florida 33781, United States
  • East Coast Institute for Research, LLC
    Saint Augustine, Florida 32086, United States
  • DBC Research
    Tamarac, Florida 33321, United States
  • Bayside Clinical Research - New Port Richey
    Tampa, Florida 33604, United States
  • Atlanta Gastroenterology Specialists, PC
    Atlanta, Georgia 30308, United States
  • Infinite Clinical Trials
    Atlanta, Georgia 30349, United States
  • Atlanta Center For Gastroenterology PC
    Decatur, Georgia 30033, United States
  • Loretto Hospital
    Chicago, Illinois 60644, United States
  • IL Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Laporte County Institute For Clinical Research
    Michigan City, Indiana 46360, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Gastroenterology Associates of Hazard
    Hazard, Kentucky 41701, United States
  • CroNOLA, LLC.
    Houma, Louisiana 70360, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • DelRicht Clinical Research, LLC - ClinEdge - PPDS
    New Orleans, Louisiana 70115, United States
  • Louisiana Research Center LLC
    Shreveport, Louisiana 71103, United States
  • Commonwealth Clinical Studies LLC
    Brockton, Massachusetts 02302, United States
  • Winchester Gastroenterology Associates
    Winchester, Massachusetts 22601, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • National Clinical, LLC
    Hamtramck, Michigan 48212, United States
  • Gastroenterology Associates of Western Michigan, PLC
    Wyoming, Michigan 49519, United States
  • Mayo Clinic Health System - PPDS
    Duluth, Minnesota 55805, United States
  • Minnesota Gastroenterology PA
    Saint Paul, Minnesota 55114, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89123, United States
  • Encompass Care
    North Las Vegas, Nevada 89086, United States
  • New York Total Medical Care PC
    Brooklyn, New York 11215, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Southtowns Gastroenterology, PLLC
    Orchard Park, New York 14127, United States
  • Piedmont Healthcare
    Statesville, North Carolina 28625, United States
  • Consultants For Clinical Research Inc
    Cincinnati, Ohio 45219, United States
  • Consultants For Clinical Research Inc
    Cincinnati, Ohio 45249, United States
  • Consultants For Clinical Research Inc
    Fairfield, Ohio 45014, United States
  • Penn State Hershey Medical Group
    State College, Pennsylvania 16803, United States
  • Digestive Disease Associates
    Wyomissing, Pennsylvania 19610, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Advanced Gastroenterology-Union City
    Union City, Tennessee 38261, United States
  • Northside Gastroenterology
    Cypress, Texas 77429, United States
  • Digestive Health Associates of Texas, P.A.dba DHAT Research Institute
    Garland, Texas 75044, United States
  • Precision Research Institute, LLC
    Houston, Texas 77039, United States
  • Biopharma Informatic Inc.
    Houston, Texas 77043, United States
  • Southwest Clinical Trials
    Houston, Texas 77074, United States
  • BI Research Center
    Houston, Texas 77084, United States
  • Southern Star Research Institute LLC
    San Antonio, Texas 78229, United States
  • Inquest Clinical Research/Coastal Gastroenterology Associates, PA - TDDC - PPDS
    Webster, Texas 77598, United States
  • HP Clinical Research
    Bountiful, Utah 84010, United States
  • Mid Atlantic Health Specialists
    Galax, Virginia 24333, United States
  • Fundación Favaloro
    Buenos Aires, C1093AAS, Argentina
  • Hospital Privado Centro Médico de Córdoba
    Córdoba, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • St Vincents Hospital Melbourne - PPDS
    Fitzroy, Victoria 3065, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • LKH-Universitätsklinikum Klinikum Graz
    Graz, Steiermark 8036, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Vienna, Wien A-1090, Austria
  • Salzburger Landeskliniken
    Salzburg, 5020, Austria
  • Medizinische Universitat Wien (Medical University of Vienna)
    Wien, 1090, Austria
  • Academisch Medisch Centrum Amsterdam
    Bonheiden, Antwerpen 2820, Belgium
  • UZ Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • AZ Groeninge
    Kortrijk, West-Vlaanderen 8500, Belgium
  • CHU Mouscron
    Mouscron, 7700, Belgium
  • Clinical Center Banja Luka
    Banja Luka, 78000, Bosnia and Herzegovina
  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment EOOD
    Sofia, Sofia-Grad 1784, Bulgaria
  • Multiprofile Hospital for Active Treatment Eurohospital
    Plovdiv, 4004, Bulgaria
  • Second Multiprofile Hospital for Active Treatment Sofia
    Sofia, 1202, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
    Sofia, 1527, Bulgaria
  • Medical Center Excelsior OOD - PPDS
    Sofia, 1632, Bulgaria
  • Medical Center Convex EOOD
    Sofia, 1680, Bulgaria
  • Diagnostic Consultative Centre Mladost - M OOD
    Varna, 9000, Bulgaria
  • Fundación Valle Del Lili
    Cali, Valle Del Cauca 760026, Colombia

Showing the first 100 of 281 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jun 2021, 28 months.

Results were first posted in Mar 2022, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2018
First posted
Aug 13, 2018
StartActual
Feb 6, 2019
Primary completionActual
Jun 21, 2021
CompletionActual
Sep 13, 2021
Results first posted
Mar 31, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03627091
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Aug 13, 2018
Start date
Feb 6, 2019
Primary completion
Jun 21, 2021
Completion
Sep 13, 2021
Results posted
Mar 31, 2022
Last update
Mar 31, 2022

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion